ANN ARBOR, Mich., April 20, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement with TG United, Inc. of Brooksville, Florida, to provide commercial-scale manufacturing capabilities for reaZin. Adeona is developing reaZin, its product candidate for the dietary management of Alzheimer's disease and mild cognitive impairment, as a prescription medical food.
Top-line results from Adeona's clinical study evaluating reaZin for the dietary management of Alzheimer's disease and mild cognitive impairment were presented last week at the 63rd Annual Meeting of the American Academy of Neurology. In the patients administered reaZin, the primary outcome of increasing serum zinc and decreasing serum free copper was effectively demonstrated. In addition, the average cognitive function of the placebo group declined over 6 months in comparison to patients managed with reaZin. The cognitive function trends favoring the patients administered reaZin were observed in all three standardized cognitive tests and suggest that reaZin may provide an important dietary benefit to Alzheimer's disease patients.
"Executing this agreement for the manufacturing of our product candidate, reaZin, is an important step for commercialization," stated James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer. "With the recent news that revised guidelines for diagnosing Alzheimer's disease could double the population size, we are excited that reaZin may be of benefit to this growing population, particularly in the earlier stages."
About Medical Foods
A medical food (1) is intended for the specific dietary management of a disease or condition for which distinctive nutritional requir